Company intelligence / Profile preview

Phebra

Sydney, New South Wales, Australiaphebra.com ↗

Ownership: Private
Employees: ~120
Development stage: Other

Overview

Phebra manufactures and supplies over 65 critical medicines for hospital specialty use. It has a strong presence in Australia and export markets. The company is involved in licensing agreements with partners such as Medsenic for the oral formulation of arsenic trioxide targeting several autoimmune and inflammatory conditions. Its Lane Cove West facility is GMP-compliant and licensed by the Australian TGA.

Therapeutic areas: ImmunologyRheumatologyInfectious DiseasesNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

2 assets

papaverine

1 more asset in the full pipeline.

Request access →

Partnerships

Medsenic/BioSenic Group – licensing agreement for oral arsenic trioxide ("OATO")

Beyond the preview

Go deeper on Phebra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phebra.

Explore the full profile